Transcriptomic analysis of pathway activation after decitabine treatment in EBV+ vs EBV- gastric cancer [RNA-Seq]
Epstein-Barr virus associated gastric cancer (EBVaGC) accounts for ~9–10% of gastric cancers worldwide and is defined by a distinctive molecular profile, including extreme hypermethylation of the DNA. Targeting this aberrant methylation may be a potential therapeutic strategy. EBV ? gastric cancer cell lines (YCCEL1, SNU719) and EBV ? lines (AGS, SNU16, HGC27) were treated with a DNA methyl-transferase inhibitor (DNMT), decitabine (DCB), for three days followed by RNA sequencing to identify EBV-specific responses. Overall design: EBV+ cell lines (YCCEL1 and SNU719) and EBV- cell lines (AGS, SNU16 and HGC27) were treated with DCB for 72 hours or DMSO as the control.